These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17499714)

  • 1. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology.
    Scatena R; Bottoni P; Martorana GE; Vincenzoni F; Botta G; Pastore P; Giardina B
    Eur J Pharmacol; 2007 Jul; 567(1-2):50-8. PubMed ID: 17499714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications.
    Scatena R; Bottoni P; Martorana GE; Ferrari F; De Sole P; Rossi C; Giardina B
    Biochem Biophys Res Commun; 2004 Jul; 319(3):967-73. PubMed ID: 15184076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
    Scatena R; Martorana GE; Bottoni P; Giardina B
    IUBMB Life; 2004 Aug; 56(8):477-82. PubMed ID: 15545227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
    Strakova N; Ehrmann J; Bartos J; Malikova J; Dolezel J; Kolar Z
    Neoplasma; 2005; 52(2):126-36. PubMed ID: 15800711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration.
    Nadanaciva S; Dykens JA; Bernal A; Capaldi RA; Will Y
    Toxicol Appl Pharmacol; 2007 Sep; 223(3):277-87. PubMed ID: 17658574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines.
    Atarod EB; Kehrer JP
    Free Radic Biol Med; 2004 Jul; 37(1):36-47. PubMed ID: 15183193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
    Scatena R; Bottoni P; Giardina B
    PPAR Res; 2008; 2008():256251. PubMed ID: 18645611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists.
    Bottoni P; Giardina B; Martorana GE; Zuppi C; De Sole P; Rossi C; Scatena R
    J Cell Mol Med; 2005; 9(2):462-7. PubMed ID: 15963265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
    Ibabe A; Herrero A; Cajaraville MP
    Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator.
    Scatena R; Bottoni P; Vincenzoni F; Messana I; Martorana GE; Nocca G; De Sole P; Maggiano N; Castagnola M; Giardina B
    Chem Res Toxicol; 2003 Nov; 16(11):1440-7. PubMed ID: 14615970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists modulate human osteoclast formation and activity in vitro.
    Chan BY; Gartland A; Wilson PJ; Buckley KA; Dillon JP; Fraser WD; Gallagher JA
    Bone; 2007 Jan; 40(1):149-59. PubMed ID: 17010686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M; Gutman W; Derlacz RA
    Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.